Lysaght is a UK takeover specialist, Meilman is a managing director at the bank. Monaghan has advis…

"With 2019 annual combined revenue of approximately $48 billion, scale in more than 175 countries, …

If everything goes as planned, the deal will give the $45-billion Pfizer the tax benefits of an Iri…

Allegan said last week it was planning to sell off two businesses it considers non-core to the comp…

Allergan is making big push to try and introduce new consumers to the world of Botox. This includes…

Business Insider spoke with half a dozen funds with top 50 positions in Allergan who said they have…

AbbVie didn't want to take "a lot of binary risks" such as researching new, experimental drugs, "be…

When it came to Allergan's announcement earlier in April that it was in the "in the early stages of…

DUBLIN and IRVINE, Calif., Nov. 17, 2014 /PRNewswire/ -- Actavis plc (NYSE:ACT) and Allergan, Inc. …

Allergan is currently fending off a takeover bid from Valeant and activist investor Bill Ackman, wh…

"The acquisition of LifeCell is both strategically and financially compelling to Allergan and serve…

Activist investor Bill Ackman has a major stake in Allergan and has been pressuring the Botox maker…

William Ackman, founder and CEO of hedge fund Pershing Square Capital Management, speaks at the Soh…

Back in April, hedge fund manager Bill Ackman, who runs $12 billion Pershing Square, teamed up with…

Saunders: I understand why you would do it. To be fair, not all drugs are created equal. Some of th…

It's an interestingly-timed development, considering the hit absorbed by Allergan's drug pipeline o…

According to research provider Dealogic, AbbVie's lead adviser Morgan Stanley, could stand to make …

Targeting consumers who are just starting to consider Botox is just step one for the company, Meury…

Pyott, who served as chief executive of Allergan from 1998 to 2015, declined to comment when Busine…

Big companies often tout cost cuts as they make the case to Wall Street that they're striking smart…